This page includes news on developments in drug treatments for chronic gastrontestinal illnesses. No endorsement is intended or implied.
To find clinical trials and other research studies currently recruiting participants, go to our webpage at Research.
Developments in drug treatments for functional GI and motility disorders.
- September 18, 2018 — Teduglutide (Gattex) has been approved in South Korea by the Ministry of Food and Drug Safety for the treatment of short bowel syndrome (SBS).
- September 18, 2018 — Linaclotide (Linzess) has been approved in Japan for the treatment of adult patients with chronic constipation.
- September 18, 2018 — The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) for an investigational nasal spray formulation of metoclopramide (Gimoti) for the treatment of adult women with acute or recurrent diabetic gastroparesis.
- December 16, 2015 — The new FDA approved drug, eluxadoline (Viberzi), is available for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in men and women.